SCHEMBL17722908

SCHEMBL17722908

CC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)CCN1C(=O)C=CC1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS1 P23219 7/20 0.36
▸ PTGS2 P35354 7/20 0.36
▸ FNTA P49354 3/20 0.36
▸ FNTB P49356 3/20 0.36
▸ KDM4E B2RXH2 2/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ MGLL Q99685 4/20 0.34
▸ FAAH O00519 3/20 0.34
▸ ALDH1A1 P00352 2/20 0.33
▸ HSP90AA1 P07900 1/20 0.33
▸ TLR9 Q9NR96 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ PKM P14618 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ XBP1 P17861 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ RECQL P46063 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26645911 0.89 KDM4E (0.44) PTGS1PTGS2FNTAFNTBKDM4E
SCHEMBL26645910 0.89 KDM4E (0.44) PTGS1PTGS2FNTAFNTBKDM4E
SCHEMBL20960454 0.89 PTGS1 (0.36) PTGS1PTGS2FNTAFNTBKDM4E
SCHEMBL20132347 0.88 FNTA (0.42) PTGS1PTGS2FNTAFNTBMGLL
SCHEMBL27415852 0.88 FNTA (0.42) PTGS1PTGS2FNTAFNTBMGLL
SCHEMBL16006834 0.87 HRH1 (0.36) PTGS1PTGS2FNTAFNTBKDM4E
SCHEMBL18932739 0.87 FNTA (0.38) PTGS1PTGS2FNTAFNTBKDM4E
SCHEMBL20132239 0.86 ALDH1A1 (0.36) PTGS1PTGS2FNTAFNTBKDM4E
SCHEMBL22596587 0.86 AKT1 (0.37) PTGS1PTGS2KDM4EMGLLFAAH
SCHEMBL26231710 0.86 AKT1 (0.37) PTGS1PTGS2KDM4EMGLLFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024137502-A2 PNU ANTHRACYCLINE-DERIVED LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF MERCK SHARP & DOHME LLC (US) 2024-06-27 — — WO disclosed
US-20230321271-A1 ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE ABBVIE BIOTHERAPEUTICS INC. (US) 2023-10-12 — — US disclosed
US-20230321271-A1 ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE ABBVIE BIOTHERAPEUTICS INC. (US) 2023-10-12 — — US disclosed
EP-4233909-A2 ANTI-CMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE AbbVie Biotherapeutics Inc. (US) 2023-08-30 — — EP disclosed
EP-3901162-A1 GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF AbbVie Inc. (US) 2021-10-27 — — EP disclosed
EP-3804765-A1 ANTI-CMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE AbbVie Biotherapeutics Inc. (US) 2021-04-14 — — EP disclosed
EP-3626273-B1 ANTI-CMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE ABBVIE BIOTHERAPEUTICS INC (US) 2020-12-30 — — EP disclosed
WO-2020236795-A2 TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF NOVARTIS AG (CH) 2020-11-26 — — WO disclosed
EP-3383909-B1 ANTI-HUMAN LRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE ABBVIE INC (US) 2020-06-17 — — EP disclosed
EP-3458102-B1 ANTI-CMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE ABBVIE BIOTHERAPEUTICS INC (US) 2020-06-17 — — EP disclosed
US-20170348429-A1 ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE AbbVie Manufacturing Management Unlimited Company (IE) 2017-12-07 — — US disclosed
WO-2017201204-A1 ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE ABBVIE BIOTHERAPEUTICS INC. (US) 2017-11-23 — — WO disclosed
US-20170151344-A1 ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE ABBVIE INC. 2017-06-01 — — US disclosed
US-20170151343-A1 ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE ABBVIE INC. 2017-06-01 — — US disclosed
US-20160122430-A1 ANTI-CS1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES ABBVIE BIOTHERAPEUTICS INC. 2016-05-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170151343-A1 ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE LRRC59, LRRC47, HACD3 PTGS1 4828/4885PTGS2 4820/4885FNTA 1731/4885
US-20170151344-A1 ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE LRRC59, LRRC47, HACD3 PTGS1 4828/4885PTGS2 4820/4885FNTA 1731/4885
US-20160122430-A1 ANTI-CS1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES CD47, CSGALNACT1, CSE1L PTGS1 4460/4885PTGS2 4772/4885FNTA 2932/4885
US-20170348429-A1 ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE MMAB, HNMT, SHMT1 PTGS1 4776/4885PTGS2 4741/4885FNTA 153/4885
US-20230321271-A1 ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE MMAB, HNMT, SHMT1 PTGS1 4776/4885PTGS2 4741/4885FNTA 153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback